Exact Mass: 587.2665076000001
Exact Mass Matches: 587.2665076000001
Found 48 metabolites which its exact mass value is equals to given mass value 587.2665076000001
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
H-Gly-Arg-Gly-Asp-D-Ser-Pro-OH
GRGDSP, a synthetic linear RGD peptide, is an integrin inhibitor.
Asp Lys Tyr Tyr
Asp Tyr Lys Tyr
Asp Tyr Tyr Lys
Phe Phe Phe Gln
Phe Phe Gln Phe
Phe Gln Phe Phe
Lys Asp Tyr Tyr
Lys Tyr Asp Tyr
Lys Tyr Tyr Asp
Gln Phe Phe Phe
Arg Ser Tyr Tyr
C27H37N7O8 (587.2703482000001)
Arg Tyr Ser Tyr
C27H37N7O8 (587.2703482000001)
Arg Tyr Tyr Ser
C27H37N7O8 (587.2703482000001)
Ser Arg Tyr Tyr
C27H37N7O8 (587.2703482000001)
Ser Tyr Arg Tyr
C27H37N7O8 (587.2703482000001)
Ser Tyr Tyr Arg
C27H37N7O8 (587.2703482000001)
Tyr Asp Lys Tyr
Tyr Asp Tyr Lys
Tyr Lys Asp Tyr
Tyr Lys Tyr Asp
Tyr Arg Ser Tyr
C27H37N7O8 (587.2703482000001)
Tyr Arg Tyr Ser
C27H37N7O8 (587.2703482000001)
Tyr Ser Arg Tyr
C27H37N7O8 (587.2703482000001)
Tyr Ser Tyr Arg
C27H37N7O8 (587.2703482000001)
Tyr Tyr Asp Lys
Tyr Tyr Lys Asp
Tyr Tyr Arg Ser
C27H37N7O8 (587.2703482000001)
Tyr Tyr Ser Arg
C27H37N7O8 (587.2703482000001)
SCH772984
SCH772984 is a highly selective and ATP-competitive ERK inhibitor, with IC50s of 4 and 1 nM for ERK1 and ERK2, respectively. SCH772984 has antitumor activity in MAPK inhibitor-na?ve and MAPK inhibitor-resistant cells containing BRAF or RAS mutations[1].
[(2S)-1-oxo-1-[[(2S,10R,12S,14S)-12,16,19-trihydroxy-7,14,18-trimethoxy-6,17,21-trimethyl-5,8-dioxo-11,21-diazapentacyclo[11.7.1.02,11.04,9.015,20]henicosa-4(9),6,15(20),16,18-pentaen-10-yl]methylamino]propan-2-yl]azanium
N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide
C30H36F3N5O4 (587.2719251999999)
2-[(2R,4aS,12aS)-8-[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]amino]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(5,6,7,8-tetrahydronaphthalen-2-yl)acetamide
N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide
C30H36F3N5O4 (587.2719251999999)
N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide
C30H36F3N5O4 (587.2719251999999)
N-[(5S,6R,9R)-5-methoxy-3,6,9-trimethyl-8-(4-methylphenyl)sulfonyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide
C30H41N3O7S (587.2665076000001)
(1r,3r,4s,5r,8s,9r,10r,11r,14r,16s,17r,18r,19r)-4,10,19-tris(acetyloxy)-9,18-dihydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-3-yl (2r)-2-methylbutanoate
C31H41NO10 (587.2730326000001)
(1r,2s,3s,4r,5r,6s,7s,8s,9r,10r,13s,17r,18r)-8-(acetyloxy)-2,5,7-trihydroxy-6,18-dimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-4-yl benzoate
C31H41NO10 (587.2730326000001)
(1r,3r,4s,5r,8s,9r,10r,11r,14r,16s,17r,18r,19r)-4,10,19-tris(acetyloxy)-9,18-dihydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-3-yl (2s)-2-methylbutanoate
C31H41NO10 (587.2730326000001)
4,10,19-tris(acetyloxy)-9,18-dihydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-3-yl 2-methylbutanoate
C31H41NO10 (587.2730326000001)